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Variation in topoisomerase I gene copy number as a mechanism for intrinsic
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Summary DNA topoisomerase I (topo I) is the principle target for camptothecin and its derivatives such as
SN38. Levels of topo I expression vary widely between and within tumour types and the basis for this is poorly
understood. We have used fluorescence in situ hybridisation to detect the topo I locus in a panel of breast and
colon cancer cell lines. This approach has identified a range of topo I gene copies from 1 to 6 between the cell
lines as a result of DNA amplification, polysomy and isochromosome formation. Topo I gene copy number
was highly correlated with topo I expression, (r, =0.92), and inversely correlated to sensitivity to a 1 h exposure
to SN38 (r, = -0.904). This illustrates the significant impact of altered topo I gene copy number on intrinsic
drug sensitivity and influences potential mechanisms for acquisition of drug resistance.
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DNA topoisomerase I (topo I) is a nuclear enzyme that
catalyses the breakage and rejoining of DNA, allowing the
strands to pass through one another. In normal cells, topo I
activity is probably required for gene transcription and
possibly for DNA synthesis and replication (Slichenmyer et
al., 1993). The topo I inhibitors are an exciting new class of
antineoplastic agents with activity in patients with refractory
solid tumour malignancies (reviewed in Potmesil, 1994).
Human cancer cell lines with acquired resistance to topo I
inhibitors in vitro have demonstrated point mutations in the
topo I gene or down-regulation of topo I expression
(reviewed in Pommier et al., 1994). Whereas these mechan-
isms of resistance may have clinical relevance in long-term
treatment with topo I inhibitors, they provide little insight
into the mechanisms for intrinsic resistance to topo I
inhibition. One postulated source of altered senstivity to
topo I inhibitors is variable topo I expression. A wide range
of topo I protein expression and catalytic activity has been
observed in human tumours, with significant variation within
specific tumour types (McLeod et al., 1994; Husain et al.,
1994). The basis for variable expression of topo I has not
been elucidated. Genetic alterations in the region of the
topo I locus on chromosome 20q have been reported in
breast cancer biopsies and cell lines (Devilee et al., 1991;
Keith et al., 1993; Tanner et al., 1994; Kallioniemi et al.,
1994), but there is relatively little information on direct
changes to the topo I locus, (Keith et al., 1993). Therefore,
we examined four breast cancer cell lines available in our
laboratory for alterations at the topo I locus in an attempt to
generate valuable well-characterised cell line models for the
study of drug sensitivity. In addition, the colon cancer cell
line HT29 was included in the study as it is routinely used in
a number of laboratories for topoisomerase studies,
(Tanizawa et al., 1994). In this study we demonstrate altered
topo I gene copy number in human breast and colon
carcinoma cell lines and establish correlations between copy
number, protein expression and intrinsic sensitivity to topo I
inhibition, thereby providing evidence for alterations in
topo I gene copy number as a mechanism for intrinsic
resistance to topo I-directed therapy.
Materials and methods
Cell lines and chemicals
Four human breast carcinoma cell lines (MCF-7, ZR75-1,
MB MDA231, MB MDA436) and one human colon
carcinoma cell line (HT29) were obtained from the American
Type Culture Collection (Rockville, MD, USA) and
maintained as previously described (McLeod et al., 1994).
All chemicals were obtained from Sigma (Dorset, UK) and
were of the highest available grade. The topo I inhibitor
SN38 was a kind gift from Dr J-F Riou, Rh6ne-Poulenc
Rorer Bellon (Neuilly sur Seine, France). SN38 is the active
metabolite of CPT 1, a potent analogue of camptothecin,
and has a high level of specificity for inhibition of topo I
(Potmesil, 1994).
Cytotoxicity assay
The cytotoxic activity of SN38 was determined by the MTT
assay (Plumb et al., 1989). Multiwell plates were seeded at
1 x 103 cells per well and maintained for 48 h. Cells were then
exposed to drug at 0.000128 -10jIM for 1 to 24 h. Cells were
then maintained in drug-free medium for 72 h. Reduction of
tetrazolium dye was determined after addition of MTT to
each well for 4 h, solubilised in dimethyl sulphoxide (DMSO)
and glycine buffer and measured at 570 nm. The concentra-
tion lethal to 50% of cells (IC50) was determined using the
signoidal Hill equation.
Topo I protein analysis
Nuclear protein extracts were prepared as previously
described (Van der Zee et al., 1991). Extracted nuclear
protein (50,g) was separated by 7.5% sodium dodecyl
sulphate (SDS) polyacrylamide gel electrophoresis and
protein transferred to immobilon P PVDF nylon membranes
(Millipore, Watford, UK) at 200 mA for 45 min at room
temperature by using a semidry-blot system. Topo I was
detected using a polyclonal antibody from scleroderma
patient serum (1:1000;TopoGEN, Columbus, OH, USA).
The enhanced chemiluminescence Western blotting system
(Amersham, Little Chalfont, UK) was used to detect topo I,
using protein A conjugated horseradish peroxidase as the
secondary antibody. Quantitation was performed by auto-
radiograph scanning (Molecular Dynamics, UK) and
expressed in arbitrary units. Protein analysis was performed
in duplicate for two separate culture flasks of each cell line.
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Figure 1 Detection and mapping of the topoI locus by FISH. (a) Metaphase spread from lymphocytes, (b) an intensity plot of
fluorescence along the profile of chromosome 20. Horizontal axis shows the length along which fluorescence intensity is measured
from the p-arm telomere and the vertical axis shows fluorescence intensity. The chromosome profile generated by the DNA
counterstain, propidium iodide is shown as is the hybridisation site for topo I. Thus, a visual representaiton of the hybridisation site
for topo I relative to the chromosome 20 profile is generated. Flpter analysis of topoI gave a mean value of0.64. For comparison an
ideogram ofchromosome 20 with the approximate map positions of topo I, SRC and PTPN 1 is shown below the intensity plot. (c)
Metaphase spread from the MB MDA231 cell line which has four copies of topo I, the isochromosome 20q is marked *. (d, e, f, g, h,
i) Details of the chromosomes carrying multiple copies of topoI. (d) Lymphocytes. (e) MBMDA436. (f) MCF7. (g) ZR75-1. (h)
MB MDA231. (i) HT29. Fluorescence was detected using a confocal microscope and the chromosomes are pseudocoloured red,
hybridisation sites green. (fl The two chromosomes in MCF7 that carry more than one copy of topo I. The MCF7 chromosome in
the inset of (f) has the low level amplicon with three copies. Two of the hybridisation sites on one of the sister chromatids are out of
the plane or focus used for image capture. (h) One end of the small chromosome from MBMDA231 containing the two copies of
topo I is indistinct as it partially overlaps a neighbouring chromosome, (see (c) for an example of a metaphase spread).
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Fluorescence in situ hybridisation
The topo I probe used for fluorescence in situ hybridisation
(FISH), was a phage clone designated TP3.6, (kindly
provided by Dr N Kunze), which contains genomic DNA
encompassing the third exon of the functional topo I gene,
(Kunze et al., 1991). The sequences present in this clone are
not present in the two topo I pseudogenes and do not cross-
hybridise with them. Probe labelling, in situ hybridisation and
probe detection are as previously described, (Coutts et al.,
1993; Murphy et al., 1995), using the Hybaid Omnislide
system (Hybaid Ltd, Teddington, UK). The topo I probe was
localised by fractional length measurements, Flpter, where
the Flpter is the distance from the probe location to the end
of the short arm of chromosome 20 divided by the total
length of the chromosome, (Lichter et al., 1990; Mascio et al.,
1995; Sakamoto et al., 1995). Analysis of digitised images for
Flpter measurements was carried out using IPLab Spectrum
software with SmartCapture extension from Digital Scientific
(Cambridge, UK). Images were processed using edge
enhancement algorithms (Comos Software, Bio-Rad) to aid
definition of chromosome boundaries and hybridisation sites
and length measurements carried out using IPLab spectrum.
In addition, GraphPolygon was used to produce an intensity
plot along the profile of the chromosome where the width of
the chromosome was determined in pixels and the average
intensity over the width plotted. Thus, a visual representation
of the hybridisation site relative to the chromosome profile is
generated, (see Figure lb). The unit of measurement is 1
pixel.
Statistics
The correlation between gene copy number, topo I protein
content, and cytotoxicity was assessed by the Spearman rank
correlation test.
Results
Detection and mapping of the topo I locus
Topo I sequences were detected by FISH using a phage
clone designated TP3.6, (Kunze et al., 1991). Figure la
shows an example of detection of topo I sequences in
normal lymphocyte chromosomes by FISH. Hybridisation
efficiency for TP3.6 on lymphocytes is 85% when efficiency
is defined as the percentage of metaphase spreads with both
chromosome 20 homologues and both chromatids labelled.
Forty metaphase spreads were analysed.
Juan et al. (1988) and Kunze et al. (1989), have
previously mapped the topo I locus to chromosome bands
20qll.2-ql3.2 by isotopic in situ hybridisation. With the
rapid progress in molecular cytogenetics and the use of
FISH to assemble physical maps, standard ideograms are
often unsuitable for the description of probe localisation. An
appealing and robust approach to mapping probe localisa-
tion by FISH is to define the map position of the
hybridisation signal as the fractional length along the
Table I Topoisomerase I copy number, protein expression and
sensitivity to SN38 in human breast and colon cell lines
Copy Protein
Cell line number expressiona SN38 IC50b SN38 ICsoc
MCF7 6 3.26 (0.9) 1.68 (0-52) 0-35 (0-24)
ZR75-1 5 2.45 (0.17) 35.5 (6.5) 51.5 (34.5)
MB MDA231 4 1.83 (0.040) 461 (249) 33.9 (5.8)
MB MDA436 1 1.25 (0.1) 31700 (5000) 10 (1.1)
HT29 5 2.99 (0.7) 640 (160) 53 (8.1)
aMean (s.d.) arbitrary units. bMean (s.e.) LuM; 1 h exposure. cMean
(s.e.) nM.
chromosome in relation to the short arm telomere, (Flpter;
Lichter et al., 1990). Flpter measurements were carried out
on digitised images using length measurement and Graph-
Polygon extensions within IPLab Spectrum. Figure lb shows
an intensity plot of fluorescence along the profile of
chromosome 20 produced using GraphPolygon. Thus, a
visual representation of the hybridisation site for topo I
relative to the chromosome 20 profile is generated. Flpter
analysis of topo I gave a mean value of 0.64, (seven
chromosomes measured, standard error, 0.048). This
localisation for topo I is consistent with the published
Flpter maps available from the Resource for Molecular
Cytogenetics at Lawrence Berkeley National Laboratories
and the University of California, San Francisco, (Internet
conection, http://rmc-www.lbl.gov/).
Topo I gene copy number in breast and colon cancer cell lines
Quantitation of topo I gene copy number was carried out by
FISH on chromosome spreads prepared from normal
lymphocytes, four breast cancer cell lines (MB MDA436,
MB MDA231, ZR75-1, MCF7) and the HT29 colon
carcinoma cell line. Figure 1 shows examples of detection
of topo I gene copies by FISH. Topo I gene copy number
varied from one to six copies in the human cancer cell lines
(Table I). Interestingly, analysis of the topo I locus by FISH
in the cell lines revealed structural as well as numerical
changes to chromosome 20 that are responsible for the
number of topo I genes in each cell line. The MCF7 breast
cancer cell line had six copies of the topo I gene, three of
which were localised to one chromosome as a low level
amplicon and two copies on another chromosome. These
structuraly aberrant chromosomes are shown in Figure 1f. In
addition, a chromosome containing a single copy of the
topo I locus was also present. A striking feature of the three
cell lines, ZR75-1, MB MDA321 and HT29 was the presence
of a small chromosome with two copies of topo I, most
probably a result of isochromosone 20q formation or some
other form of translocation event (Mertens et al., 1994).
These chromosomes are shown in Figure lc, g, h and i, and
contribute two gene copies to each line, with the remaining
<-200
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Figure 2 Western blot analysis of topo I expression. Lane 1,
MCF7; lane 2, ZR75; lane 3, MBMDA231; lane 4, MBMDA436;
lane 5, HT29. Molecular weight markers are shown to the right of
the figure and are in kDa.copies found as single copies on separate chromosomes.
Thus, for example the MB MDA231 cell line has two
chromosomes each with one copy and an isochromosome
20q with two copies as shown in Figure lc and lh.
Relationship between topo I gene copy number, topo I
expression and cellular sensitivity to the topo I inhibitor SN-38
Topo I protein expression was determined by Western blot
analysis (Figure 2). A 2.6-fold range in topo I protein levels
was observed in nuclear extracts (Table I). Topo I protein
expression was highly correlated with gene copy number
(rs=0.92; Table II, Figure 3a). The cytotoxic effect of SN38
was highly variable with a 4-log range of ICso values after a
1 h drug exposure and a 150-fold range in IC50 values after a
24-h drug exposure (Table I). Intrinsic sensitivity to topo I
inhibition by a 1 h exposure to SN38 was inversely related to
both topo I protein expression (rs= -0.81, Table II), and
gene copy number (rs= -0.904, Table II, Figure 3b). This
relationship was not apparent after a 24 h drug exposure,
(Table II).
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Discussion
This study shows a significant relationship between topo I
copy number, topo I protein expression, and cellular
sensitivity to topo I inhibition, thus demonstrating for the
first time the importance of genetic background as a
determinant of intrinsic resistance to topo I-targeting
agents. However, it is unlikely that the observed genetic
changes at the topo I locus are initial driving oncogenic
events during tumour development. Rather, gene dosage
changes at the topo I locus, including gene amplification,
isochromosome formation and polysomy, are most likely due
to selection for alterations to chromosome 20 at for example
an oncogene in the proximity of topo I. This situation has
been shown to occur for the topo IIcx locus on chromosome
17q, which can be co-amplified along with the erbB2
oncogene in a proportion of breast cancers resulting in high
levels of topo Ilo expression, (Coutts et al., 1993; Keith et al.,
1993; Murphy et al., 1995).
Both allelic imbalances and gene amplification have been
detected on chromosome 20 in breast cancer, (Devilee et al.,
1991; Keith et al., 1993; Kallioniemi et al., 1994; Tanner et
al., 1994). Indeed, a high proportion of primary breast
cancers and cell lines show amplification of sequences
originating close to the topo I locus on chromosome 20
(Tanner et al., 1994; Kallioniemi et al., 1994). Tanner et al.
(1994) have shown the MCF7 cell line to have such an
amplicon and so provide a representative cell line model for
the in vivo situation. The three copies oftopo I clustering to a
region of an MCF7 chromosome (Figure If) are probably
included within the amplicon described by Tanner et al.
(1994), albeit at a lower copy number than other markers
closer to the selective locus. However, the present study
emphasises that fortuitious amplification of the topo I locus
in breast cancer may occur and could lead to high levels of
target for enzyme inhibition. Thus, in conjunction with other
mechanisms operating to deviate the number of topo I gene
copies from normal, the intrinsic sensitivity of tumours to
topo I-inhibitory drugs may in part be controlled at the
genetic level.
The current results also have implications for both
developmental mechanisms of resistance to topo I inhibition
and strategies for enhancing drug sensitivity. These studies
emphasise the need for genetic characterisation before
creation of resistant cell lines. If only one gene copy is
present at initiation of study, as was the case for
MB MDA436, selection for down-regulation of topo I
expression may be difficult owing to the cells normal
requirement for topo I activity, (Lee et al., 1993). Indeed,
the cell line may display some intrinsic resistance and so
further increase in resistance may only be possible through
acquired gene mutation affecting drug interaction, but not
normal catalytic activity. It has been shown in primary breast
cancer biopsies that allele loss at the topo I locus can occur,
suggesting that tumours can pass through a stage at which
they have only one copy of the topo I locus (Keith et al.,
1993). Cell lines such as MB MDA436 may therefore fulfil a
role as a model for tumours with only one copy of topo I
undergoing exposure to a topo I inhibitor.
Cell lines with multiple copies of topo I at the outset of
selection for resistance, such as MCF7 in this study, are
unlikely to mutate all gene copies as this may require up to
0
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Figure 3 Graphical representation of the relationship between,
(a) topo I gene copy number and topo I expression, (b) topoI gene
copy number and cellular sensitivity to the topoI enzyme-
interactive drug, SN38, (log IC50, 1 h exposure).
Table II Correlation between topo I gene copy number, protein
expression and sensitivity to SN38 after 1 hour (1 h) and 24 hour
(24 h) drug exposure. Spearman rank correlation test
Copy
number Protein Log IC50 I h
Protein 0.92
Log IC50 1 h -0.904 -0.81
Log IC50 24 h -0.22 -0.35 0.52
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six independent mutations to occur in one cell. In addition, it
is of interest to suggest that it may be difficult to down-
regulate all copies of topo I to a level consistent with
resistance, as a significant reduction in functional topo I may
still provide greater than normal levels of target. The simplest
mechanism by which a cell with multiple copies of topo I
could reduce topo I expression would be to lose copies of the
gene. This would of course be dependent on other genes on
the topo I-carrying chromosome. These possibilities are
clearly testable using well-characterised cell lines and may
provide models closer to the in vivo situation. However,
tumour heterogeneity is a well-recognised problem and one
not normally encountered in cell line models (Epstein et al.,
1986). The data presented in Table I suggest that if a tumour
cell population consisted of subclones with variable numbers
of topo I genes, exposure to a topo I inhibitor such as SN38
may in fact select for the cells with intrinsic resistance like
MB MDA436.
Finally, although the intrinsic resistance to a 1 h exposure
to topo I inhibition is closely associated with topo I gene
copy number, it is of interest to note that this relationship is
less apparent after a 24 h drug exposure (Table II). This
possibly suggests that a threshold number of damaging events
is reached, or other molecular determinants, such as
stimulation of a functional apoptotic pathway, become
important with prolonged drug exposure. However, the
quantity of cellular target may still have some influence on
sensitivity after 24 drug exposure when present at high levels,
as MCF7 cells had six copies of the topo I gene and an IC50
value 2 logs lower than the other cell lines (Table I).
Therefore strategies designed to optimise and enhance the use
of topo I inhibitors clearly require a greater understanding of
the relationship between the genotype and phenotype of drug
resistance.
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